Biomarker: Predictive or prognostic?

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3968-3971

  Ballman, Karla V ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BREAST METASTASIS; CANCER PROGNOSIS; CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MORTALITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84947795659     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.3651     Document Type: Article

References (8)

1. Paik S, Shak S, Tang G., et al: A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 351:2817-2826, 2004
2. Stephenson AJ, Scardino PT, Eastham J.A., et al: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715-717, 2006
3. Baselga J, Cortés J, Im SA, et al: Biomarker analyses in CLEOPATRA: A phase III, placebocontrolled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:3753-3761, 2014
4. Brugger W, Triller N, Blasinska-Morawiec M, et al: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120, 2011
5. Perez EA, Thompson EA, Ballman K.V., et al: Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 33:701-708, 2015
6. Polley MY, Freidlin B, Korn E.L., et al: Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 105:16771683, 2013
7. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
8. Peterson B, George SL: Sample size requirements and length of study for testing interaction in a 2 X k factorial design when time-to-failure is the outcome [corrected]. Control Clin Trials 14:511-522, 1993